For Research Use Only. Not for human consumption. The following summarizes published preclinical literature for laboratory research purposes only.
What It Is
CJC-1295 is a synthetic 29-amino-acid analog of human growth hormone-releasing hormone (GHRH 1-29), modified with a Drug Affinity Complex (DAC) — a maleimide-reactive group that forms a covalent bond with endogenous serum albumin. This bioconjugation strategy was designed to extend the compound’s plasma half-life far beyond that of native GHRH, which is cleared within minutes. CJC-1295 is classified in the research literature as a long-acting growth-hormone-releasing factor (GRF) analog, distinct from ghrelin-mimetic secretagogues such as ipamorelin (Endocrinology, 2005).
Summary of Published Research Findings
The foundational study identifying CJC-1295 was published in Endocrinology (2005), in which researchers synthesized maleimido derivatives of hGRF(1-29) and bioconjugated them to human serum albumin. In Sprague Dawley rats, CJC-1295 produced a four-fold increase in growth hormone (GH) area-under-curve compared to unmodified hGRF(1-29), and Western blot analysis confirmed the compound remained bound to circulating albumin for more than 24 hours post-injection (Jetté et al., Endocrinology, 2005).
A related mechanistic study examined GH secretory dynamics during continuous CJC-1295 exposure and found that pulsatile GH release patterns were preserved even as trough and mean GH levels rose — indicating the compound elevates the baseline of the GH secretory rhythm without collapsing its episodic architecture (FDA Docket FDA-2024-N-4777).
Proposed Mechanism of Action
CJC-1295 is proposed in the literature to act as a GHRH-receptor agonist on anterior pituitary somatotrophs, stimulating GH synthesis and release through the same receptor pathway as endogenous GHRH. The DAC modification’s covalent albumin binding is thought to protect the peptide from dipeptidyl-peptidase IV degradation and renal clearance, producing sustained receptor stimulation rather than the short pulsatile spike seen with unmodified GHRH fragments.
Research Use Only / Handling Note
CJC-1295 acetate is typically supplied as a lyophilized (freeze-dried) powder for laboratory research applications. This product is intended strictly for qualified laboratory research use and is not manufactured, labeled, or distributed for human or animal consumption.